We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
Exelixis (EXEL - Free Report) shares ended the last trading session 8.6% higher at $28.50. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 4.5% loss over the past four weeks.
Exelixis’ shares gained on a favorable court ruling against MSN Laboratories for a generic product of lead drug Cabometyx (related to cabozantinib). The Delaware District Court ruled in Exelixis’ favor, rejecting MSN’s challenge to three listed patents related to related to cabozantinib.
This drug developer is expected to post quarterly earnings of $0.42 per share in its upcoming report, which represents a year-over-year change of +320%. Revenues are expected to be $490.32 million, up 3.9% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Exelixis, the consensus EPS estimate for the quarter has been revised 1% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on EXEL going forward to see if this recent jump can turn into more strength down the road.
Exelixis is part of the Zacks Medical - Biomedical and Genetics industry. Inovio Pharmaceuticals (INO - Free Report) , another stock in the same industry, closed the last trading session 2.1% lower at $5.58. INO has returned -16.4% in the past month.
For Inovio, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$1.20. This represents a change of -11.1% from what the company reported a year ago. Inovio currently has a Zacks Rank of #4 (Sell).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?
Exelixis (EXEL - Free Report) shares ended the last trading session 8.6% higher at $28.50. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 4.5% loss over the past four weeks.
Exelixis’ shares gained on a favorable court ruling against MSN Laboratories for a generic product of lead drug Cabometyx (related to cabozantinib). The Delaware District Court ruled in Exelixis’ favor, rejecting MSN’s challenge to three listed patents related to related to cabozantinib.
This drug developer is expected to post quarterly earnings of $0.42 per share in its upcoming report, which represents a year-over-year change of +320%. Revenues are expected to be $490.32 million, up 3.9% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Exelixis, the consensus EPS estimate for the quarter has been revised 1% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on EXEL going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Exelixis is part of the Zacks Medical - Biomedical and Genetics industry. Inovio Pharmaceuticals (INO - Free Report) , another stock in the same industry, closed the last trading session 2.1% lower at $5.58. INO has returned -16.4% in the past month.
For Inovio, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$1.20. This represents a change of -11.1% from what the company reported a year ago. Inovio currently has a Zacks Rank of #4 (Sell).